The treatment landscape for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer has expanded significantly, with 3 FDA-approved bladder-sparing therapies now available: pembrolizumab, ...

Key Takeaways Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab ...

In this episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with Diane K. Newman, DNP, a nationally recognized expert in pelvic health, to explore the often-overlooked yet vitally ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

Key Takeaways The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant ...

Key Takeaways UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of ...

Key Takeaways The AMPLIFY trial evaluates 64Cu-SAR-bisPSMA's efficacy in detecting prostate cancer lesions in patients with biochemical recurrence. 64Cu-SAR-bisPSMA has received FDA fast track ...

In 2025, cytoreductive nephrectomy (CN) remains an integral part of the multidisciplinary management of metastatic renal cell carcinoma (mRCC). Rapid advances in systemic therapies—particularly immune ...

Clinical Challenges in Renal Mass Evaluation Main Discussion Topics: Multiple factors influence management decisions, including patient expectations, comorbidities, life expectancy, and tumor ...

Key Takeaways Vibegron treatment in men with OAB and BPH showed positive long-term safety and efficacy over 52 weeks. The extension trial involved 276 participants, with 90.6% completing the study.

Experts discuss how they communicate various treatment options for non–muscle-invasive bladder cancer (NMIBC) with patients and health care professionals.

An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes ...